Myriad Genetics, Inc. (0K3W.L) Comparison with companies in other sectors?

Myriad Genetics, Inc. has a share price of 92.18M. You can analyze Myriad Genetics, Inc. (0K3W.L) competitors across different market sectors through stock heatmaps.

What are 0K3W.L's NET and operating margins?

Myriad Genetics, Inc. (0K3W.L) operating margin is around -0.15, and net profit margin is approximately -0.12 as of the latest reports.

In what way does 0K3W.L's earnings per share (EPS) trend reflect its financial momentum?

Myriad Genetics, Inc. (0K3W.L) EPS is -0.11 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Myriad Genetics, Inc. is -41.28, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Myriad Genetics, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Myriad Genetics, Inc. like P/E which is -4.04, P/B which is 0.58, and PEG which is -0.20. Compare them with sector averages to evaluate if the stock is priced fairly.

Myriad Genetics, Inc.

0K3W.L•LSE

Healthcare

Medical - Pharmaceuticals

£4.53

£-0.04(-0.85%)

Fundamental Analysis of Myriad Genetics, Inc. (0K3W.L)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.11

P/E Ratio

-41.28

ROE

-0.14%

Net Margin

-0.12%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$414.72M

Shares OutstandingTotal number of shares issued

$92.18M

Book Value/ShareNet worth per share

$7.71

Revenue/ShareAnnual revenue per share

$9.10

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.109

Net MarginNet income as percentage of revenue

-12.20%

Operating MarginOperating income as percentage of revenue

-14.98%

ROEReturn on shareholders' equity

-14.09%

ROAReturn on total assets

-10.08%

ROCEReturn on capital employed

-14.56%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.39

Cash/ShareCash and equivalents per share

$1.004

FCF YieldFree cash flow as percentage of market cap

-8.74%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 0K3W.LFinancial Ratios Analysis details for 0K3W.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 0K3W.LSector Benchmarking details for 0K3W.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Myriad Genetics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Myriad Genetics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Myriad Genetics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Myriad Genetics, Inc.

For Myriad Genetics, Inc., essential financial indicators include EPS -0.11, PE -41.28, and ROE -0.14. These key ratios reveal insights into Myriad Genetics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Myriad Genetics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Myriad Genetics, Inc.

Metrics like Net Margin -12.20% and ROA -10.08% shed light on how well Myriad Genetics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Myriad Genetics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Myriad Genetics, Inc.

Using ratios such as P/B Ratio 0.58 and PEG Ratio -0.20, investors can assess whether Myriad Genetics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Myriad Genetics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Myriad Genetics, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.22 and Cash Flow $-0.39, provide a snapshot of Myriad Genetics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Myriad Genetics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Myriad Genetics, Inc.

Investing in Myriad Genetics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Myriad Genetics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;